Navigation Links
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Date:9/18/2007

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:

-- Markets (USA and ROW) of approved drugs and forecasts

-- Treatment costs in the USA and ROW

-- Detailed ErbB pathway analyses

-- Associations of ErbB expression and mutations with specific indications

-- EGFr/HEr2-based diagnostic/theragnostic technologies and products

-- Detailed profiles of currently approved drugs

-- Comprehensive reviews of current use of approved drugs by indication

-- Comprehensive reviews of new indications of approved drugs

-- Protocols and interim and final results from clinical trials combining

approved ErbB pathway inhibitors with novel agents.

-- Detailed profiles of over 50 agents in development targeting the ErbB

pathway, including protocols and interim and final results from

hundreds of trials

This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.


'/>"/>
SOURCE New Medicine
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
4. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
5. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
10. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
11. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
(Date:4/26/2016)... April 26, 2016 Bayer AG ... interest, taxes, depreciation and amortization. The earnings are the ... multinational,s best-selling drugs Xarelto and Eylea, drugs Bayer is ... Xarelto,s patent expiration date was extended by four years ... market is expected to reach a value of ...
(Date:4/26/2016)... YORK , April 26, 2016 /PRNewswire/ ... report "Global Microbial identification Market Size, Share, ... - Industry Insights by Product (Consumables, Instruments ... Method and Genotypic Method), by Application (Diagnostic ... and Environmental Application) and by End User ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... The ... announced it has signed a letter of intent with Moda to ... Insurance Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic ... Western Championships. The competition will be held at the University of Montana on April ... west of the Mississippi River. , In order to qualify, Varize needed to place ...
(Date:4/28/2016)... WASHINGTON, D.C., (PRWEB) , ... April 28, 2016 ... ... health systems, and the Campaign for Tobacco-Free Kids, a leading force in the ... to promote federal, state and local policies that can help reduce tobacco use. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Management solutions, announces today the availability of its latest software release, NetZoomDC ... capacity management and optimization, providing new analytical capabilities that assess complex capacity ...
(Date:4/28/2016)... ... April 28, 2016 , ... The American ... and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , ... Network. The platform is scheduled to launch in July 2016 and will be ...
Breaking Medicine News(10 mins):